ERCC2、RAD51和BAG-1基因多态性与晚期非小细胞肺癌铂类化疗敏感性的研究  

The association of ERCC2 / XPD,RAD51 and BAG- 1 in the susceptibility to platinum drugs and the genetic polymorphisms in advanced non- small cell lung cancer

作　　者：陆俊国[1] 李桃[1] 徐燕飞[1] 丁华[1] 刘继斌[1] 

机构地区：[1]南通市肿瘤医院肿瘤内科,江苏南通226361

出　　处：《现代肿瘤医学》2015年第2期203-205,共3页Journal of Modern Oncology

基　　金：南通市科技计划项目(编号:BK2012082)

摘　　要：目的:研究着色性干皮病基因(ERCC2/XPD)、DNA修复基因RAD51 codon 135以及Bcl-2结合抗凋亡基因1(Bcl-2 associated athanogene 1,BAG-1)codon 324多态性与晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)以铂类药物为基础的化疗敏感性的关联。方法:选取100例晚期NSCLC患者,使用PCR-RFLP方法检测ERCC2/XPD Lys 751 Gln、RAD51 codon 135以及BAG-1 codon 324基因多态性,应用非条件Logistic回归计算OR值及95%CI,分析不同基因型与化疗敏感性的关系。结果:100例晚期NSCLC患者中,ERCC2/XPD 751基因Lys/Lys、Lys/Gln、Gln/Gln基因型的分布频率分别为69例(69%)、26例(26%)和5例(5%);RAD51 codon 135的基因型频率分布为G/G型占67%(67/100)、G/C型33%(33/100)、未发现C/C型;BAG-1 codon 324基因型频率分布C/C型占81%(81/100)、C/T型占19%(19/100),未发现T/T型。100例NSCLC患者化疗后,其中完全缓解(CR)、部分缓解(PR)、稳定(SD)和进展(PD)患者分别为0、31、41和28例。ERCC2/XPD C/A基因型多态性与化疗敏感性具有相关性(OR=3.53,95%CI=1.58-11.46,P<0.01);BAG-1 codon 324 C/C型患者与C/T型患者的化疗有效率差异有统计学意义(P=0.036),携带C/C基因型患者比C/T基因型患者化疗敏感(OR=2.67,95%CI=1.16-8.23,P<0.05);RAD51 codon 135G/C基因型患者是G/G基因型患者化疗敏感性的2.12倍(OR=2.12,95%CI=1.08-7.41,P<0.05)。结论:ERCC2/XPD、BAG-1 codon 324以及RAD 51 codon 135基因多态性可能与晚期NSCLC铂类药物化疗敏感性有关。Objective：To evaluate the relationship of xeroderma pigmentosum group D （ERCC2/XPD）,Bcl-2 associated athanogene 1 （BAG-1） and RAD51 genetic polymorphisms and the susceptibility to platinum drugs in advanced non-small cell lung cancer.Methods：The polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） was used to analyzed the genetic polymorphisms in 100 patients with advanced NSCLC.Logistic regression model was employed to calculate the odd ratios （ORs）.Results：The allele frequencies of C/C,C/A,and A/A of ERCC2/XPD 751 Gln were 69％ （69/100）,26％ （26/100） and 5％ （5/100） respectively.The allele frequencies of C/C,C/T and T/T of BAG-1 codon 324 were 81％ （81/100）,19％ （19/100） and 0％ （0/100）,respectively.The allele frequencies of G/G,G/C and C/C of RAD51 codon 135 were 67％ （67/100）,33 ％ （33/100）and 0％ （0/100）,respectively.Of 100 patients,0 achieved complete response,31 achieved partial response,41 achieved stable response,and 28 progressive disease.The overall response rate was 31％.ERCC2/XPD C/A gene polymorphisms correlated with sensitivity to chemotherapy （OR =3.53,95 ％ CI =1.58-11.46,P ＜ 0.01）.The response rate of BAG-1 codon 324 C/C allele carriers was 2.67-fold higher than that of C/T allele carriers （OR =2.67,95％ CI =1.16-8.23,P =0.036）.RAD51 codon 135 G/C allele carriers was 2.12-fold higher than that of G/G allele carriers（OR =2.12,95％ CI =1.08-7.41,P ＜ 0.05）.Conclusion：The gene polymorphisms of ERCC2/XPD,BAG-1 and RAD51 may be closely related to the susceptibility to platinum drugs in advanced NSCLC.

关 键 词：非小细胞肺癌 ERCC2/XPD BAG-1 RAD51 基因多态性 化疗敏感性 

分 类 号：R734.2[医药卫生—肿瘤]